Art of TIL immunotherapy: SITC’s perspective on demystifying a complex treatment

In a first for solid cancers, cellular immunotherapy has entered standard of care in the treatment of patients with metastatic melanoma. The infusion of autologous tumor-infiltrating T lymphocytes (TIL) is capable of mediating durable tumor regression and is now Food and Drug Administration-approved...

Full description

Bibliographic Details
Published in:	Journal for ImmunoTherapy of Cancer
Main Authors:	Robert Brown, Marco Donia, Simon Turcotte, George Coukos, John Mullinax, Brian Gastman, James C Yang, Michael T Lotze, John B A G Haanen, Inge Marie Svane, Stephanie L Goff, Vernon K Sondak, Maartje W Rohaan, Michal Besser, Benjamin Creelan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-01-01
Online Access:	https://jitc.bmj.com/content/13/1/e010207.full

Similar Items

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer
by: Christopher A Barker, et al.
Published: (2022-07-01)

The Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of acute leukemia
by: John Barrett, et al.
Published: (2020-10-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
by: Anne Mills, et al.
Published: (2023-06-01)

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
by: Deborah Collyar, et al.
Published: (2025-03-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
by: Ronald Levy, et al.
Published: (2020-10-01)

Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision
by: James L Gulley, et al.
Published: (2024-06-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer
by: Gary D Steinberg, et al.
Published: (2021-07-01)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma
Published: (2021-01-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer
by: Lipika Goyal, et al.
Published: (2023-06-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
by: Amaia Lujambio, et al.
Published: (2021-09-01)

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule
by: Jerome Galon, et al.
Published: (2016-11-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma
by: Raffit Hassan, et al.
Published: (2022-05-01)

Correction: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer
Published: (2023-06-01)

SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery
by: Kavita Dhodapkar, et al.
Published: (2020-10-01)

Demystifying Cancer Immunotherapy for Lay Audiences
by: Kiara Ellis, et al.
Published: (2019-10-01)

Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Published: (2023-09-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
by: Omid Hamid, et al.
Published: (2023-10-01)

Biomarkers for response to TIL therapy: a comprehensive review
by: Marco Donia, et al.
Published: (2024-03-01)

A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapy
by: Pedro J Romero, et al.
Published: (2025-03-01)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors
by: Harriet Kluger, et al.
Published: (2023-03-01)

Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
by: Bart Neyns, et al.
Published: (2024-04-01)

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial
by: John Haanen, et al.
Published: (2024-03-01)

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy
by: Ranee Mehra, et al.
Published: (2023-03-01)

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Published: (2018-11-01)

Addendum 1: Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0
Published: (2025-03-01)

Towards next‐generation TIL therapy: TILs enriched in neoepitope‐specific T cells
by: Marion Arnaud, et al.
Published: (2023-01-01)

Advances in the understanding and therapeutic manipulation of cancer immune responsiveness: a Society for Immunotherapy of Cancer (SITC) review
by: Francesco M Marincola, et al.
Published: (2025-01-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
by: Frederick L Locke, et al.
Published: (2020-10-01)

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
by: Rajeev Sharma, et al.
Published: (2021-06-01)

Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit
by: Antonia R Sepulveda, et al.
Published: (2020-05-01)

SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
by: Evan J Lipson, et al.
Published: (2025-06-01)

Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)
by: James L Gulley, et al.
Published: (2022-09-01)

SITC Clinical Immuno-Oncology Network (SCION) commentary on measurement and interpretation of essential biomarkers in early clinical trials
by: Carlo Bifulco, et al.
Published: (2024-03-01)

Correction: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the society for immunotherapy of cancer (SITC) 2019 Quality Summit
Published: (2020-05-01)

Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
by: Mario Sznol, et al.
Published: (2020-05-01)

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018): Late-Breaking Abstracts
Published: (2018-12-01)

Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug development
by: Jeffrey Sosman, et al.
Published: (2023-07-01)

Demystifying Infographics
by: Amy Trost
Published: (2019-12-01)

Rhetoric Demystified
by: Rima MEDJEOUB
Published: (2019-12-01)

Demystifying Translanguaging
by: Leala Holcomb, et al.
Published: (2023-10-01)